There are three main initiatives under this program:
-Healthcare initiative: cure cancer using an AI project
-Rakuten mobile autonomous network: build a fully autonomous software-defined network
-Quantum computing: establish the fundamentals and explore real-world use cases
- OPEN POSITIONS
- There are three main initiatives under this program:
Strategic initiatives by Rakuten for developing technologies for the future
There is a dedicated group of research scientists driving strategic AI initiatives in Rakuten Institute of Technology who envisage and give form to some of the strategic bets of Rakuten. These initiatives are being undertaken to ensure Rakuten is always ahead of the technology curve.
There are three main initiatives under this program, one is healthcare initiative wherein Rakuten researchers work on the cure cancer using AI project, the second one is Rakuten mobile autonomous network wherein Rakuten researchers are working to build a fully autonomous software defined network, and lastly quantum computing in which research scientists are looking to establish the fundamentals and exploring real world use cases for quantum computing. The cure cancer initiative is being done in collaboration with Rakuten Medical Inc. which specializes in finding innovative ways in curing cancer using technology, namely photoimmunotherapy.
The goal of this initiative is to analyze medical imaging data, genomics data, proteomics data, and combine them all to predict the efficacy of treatment for a patient before treatment administered.
With this AI-enabled prediction, chances of success during the human trails of the treatment will increase, thereby making a strong case for approval of treatment technique by several medical regulatory bodies. The autonomous network initiative aims to help Rakuten mobile in building a fully autonomous network that will be self-organizing and self-healing.
With this kind of autonomy, call drops will be obviated due to optimized handover mechanisms and signals will not drop due to optimized load balancing. In case of any faults in the network, it will also have the power to heal itself, thereby reducing manual cost of repair and monitoring as well.
Together with Rakuten Mobile, we strive to create new user experiences using Rakuten’s 5G mobile network. We focus on technical management and research and development of proof-of-concept solutions that best demonstrate the use of high bandwidth, low latency, and multiple connections of 5G.
We also support the development of new 5G business cases, and find new monetization opportunities, together with various departments within the Rakuten group, academic institutions, and other external partners.
We are conducting research to achieve a truly autonomous network by using AI with Rakuten Mobile. Rakuten Mobile is the first company to try to solve this problem, enabled by its software-defined architecture of the network. User demand drives networking, communication, and data center innovations;these factors revolutionize the Telco business.
As new services and user devices are introduced daily, the demand constantly increases and the range of configuration and adaptation options grow exponentially. Thus, our goal is to build a network that handles and adapts itself to unforeseen changes autonomously.
Curing cancer is arguably one of the most challenging problems that human society is facing today. Rakuten is innovating in the fight against cancer with photo-immunotherapy treatment called Illuminox at Rakuten Medical.
Rakuten Institute of Technology contributes to this Moonshot goal by working together with Rakuten Medical to create solutions, such as multi-modal analysis, to predict patient responses to treatment for personal medicine, and computer-vision algoirthms for medical image processing.
- VIEW ALL
Development of a novel, cellular-level drug uptake quantification pipeline for accurate estimation of fluorescence-conjugated therapeutics: Data from the Phase 1b/2 open-label study ASP-1929-181SITC2023
Development of an image-based tumor microenvironment analysis coupled with peripheral flow cytometry reveals a distinct immune cell phenotype in responder patients in the Phase 1b/2 study ASP-1929-181SITC2023
Augmented Walking and Social Fitme International Journal on Advances in Systems and Measurements, vol.14, no 1 & 2, pp.69-81, 2021.